Skip to main content
. 2018 May 30;2018:9596054. doi: 10.1155/2018/9596054

Figure 2.

Figure 2

Correlations between plasminogen activator inhibitor-1 (PAI-1) and (a) high-density lipoprotein cholesterol (HDL-C), (b) apolipoprotein AI (apoAI), (c) large HDL subfraction, and (d) intermediate HDL subfraction in nondiabetic obese (●) and normal-weight controls (∆).